CoagulationDisorders near Bronx, NY

Biography: Mariam El-Ashmawy, MD PhD is a medical oncologist andtranslational scientist with specialization in the treatment of advanced skincancer and ocular melanoma. Her research investigates the complex geneticlandscape of cancer in order to develop new therapies. In the laboratory, her work has been dedicated to understanding the complex genomic landscape of cancer and developing novel targeted therapeutic strategies. Her ongoing projects include testing novel RAS pathway inhibitors in preclinical models of gastric and esophageal cancer as well as a first-in-human clinical trials for patients with NRAS mutant melanoma.

Biography: Dr. Joel Gabre, MD is an Oncology Specialist who practices in New York, NY. He is 39 years old and has been practicing for 13 years. Dr. Joel Gabre, MD is affiliated with Newyork-Presbyterian/Columbia University Medical Center.

Biography: Dr. Chen is an Assistant Professor of Medicine and medical oncologist specializing in the treatment of thoracic cancers including non-small cell lung cancer, small cell lung cancer, and mesothelioma. She received her bachelor's degree in molecular biology from Princeton University and completed her medical degree at the University of Pennsylvania, where she was inducted into the Alpha Omega Alpha Honor Society. She completed both her internal medicine residency and medical oncology fellowship at Columbia University, where she served as Chief Fellow. In addition to her clinical responsibilities, Dr. Chen has an interest in identifying novel therapies through clinical trials for patients with lung cancer and other tumor types. She received the Journal of Clinical Oncology Young Investigator Award from the American Society of Clinical Oncology in recognition of her work. Above all, Dr. Chen values her relationships with patients and their families and is dedicated to providing compassionate care that is tailored to each patient. She is proud to be part of a multidisciplinary team that works tirelessly to support patients and improve their survival and well-being.

Biography: Dr. Timothy Wang is a leading expert in gastroenterology cancer research and patient care. His research specifically focuses on transgenic/ knockout mice, stem cells, lineage tracing, bone marrow-derived cells, and FACS analysis of immune/epithelial cells in the gut. His laboratory has for decades investigated the molecular mechanisms of gastrointestinal carcinogenesis, and has been continuously funded by the NIH for 29 years and by the NCI for 14 years. His lab has worked for many years on the role of inflammation in promoting gastrointestinal neoplasia, including colon cancer. His research has defined key roles for stromal cells in tumor development, including myeloid cells. Dr. Wang is the GI Division Chief at Columbia and serves as Co-leader of the Tumor Biology and Microenvironment Program of the Herbert Irving Comprehensive Cancer Center. He also serves as director of the Columbia University NCI U54 Tumor Microenvironment (TMEN) program and directs the Barretts Esophageal Translational Research Network (BETRNet) program and the Intestinal Stem Cell Consortium (ISCC) at Columbia. In addition to his leadership at Columbia, Dr. Wang has served as President of the American Gastroenterology Association (AGA). His work has been recognized with numerous awards, including the Outstanding Investigator Award from the NCI, the Irene and Arthur Fishberg Prize for medical research, the Ruth Leff Siegel Award for pancreatic cancer research, and the William Beaumont Prize in Gastroenterology from the AGA. Over his career, he has organized numerous conferences, including conferences on Gastrin, Regulatory Peptides, AACR Symposium on Gastric Cancer, Tumor Microenvironment, and Keystone Conferences.

Biography: Dr. Sathe completed her Residency in Internal Medicine at NYP/Weill Cornell and is a graduate of Rutgers-New Jersey Medical School. She also holds a JD from Columbia Law School. Her research focuses on improving cancer care delivery and reducing disparities in treatment and outcomes.

Biography: Dr. Lentzsch is a Professor of Clinical Medicine and the Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York. She is at New York Presbyterian Hospital/ Columbia University Medical Center. After receiving her degrees from the Humboldt University/ Charit Berlin, Germany, she completed her residency and fellowship at Humboldt University. She did a research fellowship, studying the mechanism of action of thalidomide and its derivatives in multiple myeloma, in the Jerome Lipper Multiple Myeloma Center under the mentorship of Dr Kenneth Anderson at the Dana-Farber Cancer Institute, Boston, MA, USA. Dr. Lentzsch was recruited in August 2004 to the University of Pittsburgh and University of Pittsburgh Cancer Institute (UPCI), PA, USA, and served as Clinical Director of the Multiple Myeloma Program at UPCI before accepting the position as Director of the Multiple Myeloma and Amyloidosis Program at Columbia University Medical Center. She cares primarily for patients with plasma cell dyscrasia including MGUS, Multiple Myeloma, Amyloidosis, POEMS and Waldenstrom's Macroglobulinemia. Dr. Lentzsch is an internationally recognized expert in the field of Multiple Myeloma and Amyloidosis. She serves as a SWOG Myeloma Committee Member, SWOG Study Coordinator and International Myeloma Foundation "Black Swan Research Initiative" committee member. She is a member of the standing advisory board for the evaluation of Secondary Primary Malignancies associated with IMiDs.

Biography: Dr. Henick is a medical oncologist specializing in the care of patients with malignancies of the aerodigestive tract.As the Associate Director of Experimental Therapeutics and Director of Translational Research in Aerodigestive Cancers in Medical Oncology, Dr. Henick's clinical care and research are aligned to improve the effectiveness of, and limit toxicity from, emerging cancer treatments. These effortsentail clinical trials that Dr. Henick has written and leads to study novel therapeutic approaches and to reduce steroid dependence among patients experiencing adverse events fromimmunotherapy.

Biography: Meghna S. Trivedi, MD, MS cares for patients diagnosed with breast cancer. Dr. Trivedi received her medical degree from the University of Maryland School of Medicine, and completed her residency at the University of Pennsylvania. She went on to complete her fellowship in hematology/oncology at Columbia University. Dr. Trivedi co-leads the Hereditary Breast and Ovarian Cancer Program, a comprehensive, multi-disciplinary initiative aimed at screening, preventing, diagnosing, and treating hereditary breast and ovarian cancer. This innovative program brings together the resources of a world-renowned academic institution, including cutting-edge genomic testing, clinical trials, and experts in hereditary cancers across different specialties. Dr. Trivedi's research and care expertise also includes cancer genetics and genomics, precision medicine, and chemotherapy induced peripheral neuropathy. She is the principal investigator on several clinical trials, and has authored numerous publications in leading peer-reviewed journals. Dr. Trivedi is a member of the American Society of Clinical Oncologists and SWOG.

Biography: Dr. Vaibhav Patel, MD is a Hematology Specialist who practices in New York, NY. He is 38 years old. Dr. Vaibhav Patel, MD is affiliated with Mount Sinai Queens, Mount Sinai Brooklyn and Mount Sinai Hospital.